FAK/PYK2 inhibition also reduced T-ALL burden in vivo and prolonged survival of leukemic mice, pointing to FAK/PYK2 as potential therapeutic targets for T-ALL. The gene discussed is PTK2B; the disease is acute lymphoblastic leukemia.